Beryl Drugs Ltd
BERLDRGBeryl Drugs Ltd
BERLDRG
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 46.14 | 1.86 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.26 | 6.38 | 0.53% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Beryl Drugs is engaged in the manufacturing of allopathic pharmaceuticals preparations.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 13.61 | 11.39 | 15.87 | 13.20 | 13.05 | 14.73 | 14.76 | 27.14 | 27.13 | 22.81 | ||||||||||
Raw Materials | 8.80 | 6.94 | 8.83 | 6.85 | 0.94 | 0.76 | 0.90 | 1.25 | 1.48 | 20.42 | ||||||||||
| Power & Fuel Cost | 1.11 | 0.90 | 1.04 | 1.06 | 0.77 | 0.86 | 0.85 | 1.27 | 1.54 | |||||||||||
| Employee Cost | 1.15 | 1.01 | 0.77 | 0.85 | 0.97 | 1.18 | 1.31 | 1.70 | 1.93 | |||||||||||
| Selling & Administrative Expenses | 1.17 | 1.22 | 2.18 | 2.06 | 2.24 | 1.92 | 2.16 | 4.49 | 4.28 | |||||||||||
| Operating & Other expenses | 0.52 | 1.10 | 1.33 | 1.12 | 6.99 | 7.92 | 8.96 | 16.16 | 15.13 | |||||||||||
EBITDA | 0.86 | 0.22 | 1.72 | 1.26 | 1.14 | 2.09 | 0.58 | 2.27 | 2.77 | 2.39 | ||||||||||
| Depreciation/Amortization | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.24 | ||||||||||
| PBIT | 0.45 | -0.16 | 1.39 | 0.94 | 0.48 | 0.82 | -0.51 | 1.46 | 1.57 | 1.15 | ||||||||||
| Interest & Other Items | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.55 | 0.57 | ||||||||||
| PBT | 0.24 | -0.36 | 1.26 | 0.79 | 0.16 | 0.35 | -0.97 | 0.99 | 1.02 | 0.58 | ||||||||||
| Taxes & Other Items | 0.08 | 0.07 | 0.28 | 0.21 | 0.11 | 0.11 | -0.29 | 0.22 | 0.24 | 0.22 | ||||||||||
| Net Income | 0.16 | -0.43 | 0.98 | 0.58 | 0.05 | 0.24 | -0.68 | 0.77 | 0.78 | 0.36 | ||||||||||
| EPS | 0.31 | -0.84 | 1.92 | 1.14 | 0.10 | 0.47 | -1.33 | 1.50 | 1.52 | 0.70 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Beryl Drugs Ltd | 21.29 | 1.86 | — |
| Sun Pharmaceutical Industries Ltd | 44.98 | 6.42 | 0.75% |
| Cipla Ltd | 29.13 | 4.48 | 0.87% |
| Torrent Pharmaceuticals Ltd | 64.71 | 15.63 | 0.88% |
Price Comparison
Compare BERLDRG with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.74%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
BERLDRG has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Beryl Drugs declined 96.30% to Rs 0.01 crore in the quarter ended September 2024 as against Rs 0.27 crore during the previous quarter ended September 2023. Sales declined 30.14% to Rs 5.61 crore in the quarter ended September 2024 as against Rs 8.03 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5.618.03 -30 OPM %9.988.97 - PBDT0.440.62 -29 PBT0.110.33 -67 NP0.010.27 -96 Powered by Capital Market - Live
Beryl Drugs will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Beryl Drugs announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Beryl Drugs announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Beryl Drugs will hold a meeting of the Board of Directors of the Company on 3 September 2024.Powered by Capital Market - Live
Net profit of Beryl Drugs declined 30.19% to Rs 0.37 crore in the quarter ended June 2024 as against Rs 0.53 crore during the previous quarter ended June 2023. Sales declined 22.93% to Rs 6.25 crore in the quarter ended June 2024 as against Rs 8.11 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales6.258.11 -23 OPM %15.8413.93 - PBDT0.781.01 -23 PBT0.500.73 -32 NP0.370.53 -30 Powered by Capital Market - Live
Beryl Drugs will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
Beryl Drugs Standalone March 2022 Net Sales at Rs 3.47 crore, down 42.8% Y-o-Y
Beryl Drugs Standalone June 2021 Net Sales At Rs 4.61 Crore, Up 70.95% Y-o-Y
Beryl Drugs reports standalone net profit of Rs 0.34 crore in the June 2021 quarter
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 15.5%, vs industry avg of 9.03%
Constant Market Share
Over the last 5 years, market share stayed at 0.01%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 6.1%, vs industry avg of 15.28%